In an open-label , phase II , multicenter study , women with advanced breast cancer previously treated with @ lines of chemotherapy for advanced disease , including both anthracyclines and taxanes , were randomized ( @:@ ) to @-hour infusions of trabectedin @ mg/m ( @ ) once every @ weeks ( @/@ treatment arm ) or @ mg/m ( @ ) every week for @ of @ weeks ( @/@ treatment arm ) .